Thermo Fisher Scientific (NYSE: TMO) — Company Overview, News & Financial Data
Thermo Fisher Scientific provides scientific research services, offering innovative solutions for life sciences and diagnostics.
Thermo Fisher Scientific
Thermo Fisher Scientific is a global provider of life science solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. Headquartered in Waltham, Massachusetts, the company serves pharmaceutical and biotechnology firms, clinical diagnostic laboratories, universities, research institutions, and government agencies, as well as industrial process control settings. Thermo Fisher Scientific operates through major commercial channels and brand portfolios including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Its solutions support bioprocessing, cell and gene therapy, molecular testing, chromatography, spectroscopy, laboratory automation, and contract development and manufacturing organization services worldwide.
Snapshot
Operations
Products and/or services of Thermo Fisher Scientific
- Life Sciences Solutions: Provides reagents, instruments, and consumables for biological and medical research, enabling bioprocessing, cell culture and transfection, gene editing, real-time PCR, DNA and RNA sequencing, and cell and gene therapy development for biotech and biopharma customers.
- Analytical Instruments: Supplies advanced mass spectrometers, chromatography columns and systems, electron microscopes, and molecular spectroscopy instruments used in industrial applications, environmental testing, clinical diagnostics, academic research laboratories, and food safety testing worldwide.
- Specialty Diagnostics: Offers diagnostic test kits, reagents, culture media, liquid reagents, immunodiagnostic systems, and clinical oncology testing solutions used by healthcare providers, clinical diagnostic laboratories, blood banks, and public health institutions to detect diseases.
- Laboratory Products and Biopharma Services: Delivers lab equipment, plasticware, chemicals, automated liquid handling systems, and supply chain management services, combined with contract development and manufacturing services, clinical trial logistics, and drug product manufacturing for pharmaceutical companies.
- Contract Research and Clinical Development Services: Provides contract research organization and contract development and manufacturing organization capabilities through its PPD and Patheon brands, supporting global clinical trials, drug substance formulation, sterile fill-finish, and commercial packaging operations.
- Laboratory Support and Enterprise Services: Delivers integrated lab asset management, instrument maintenance, calibration, compliance, technical consulting, and lab informatics software through the Unity Lab Services and Digital Solutions platforms to optimize client laboratory efficiency and data integrity.
Thermo Fisher Scientific executive team
- Marc N. CasperChairman & CEO
- Gianluca PettitiPresident, COO & President of Products and Technologies
- James R. MeyerSenior VP & CFO
- Joseph R. HolmesVP & Chief Accounting Officer
- Ryan J. SnyderSenior VP & Chief Information Officer
- Karen E. NelsonChief Scientific Officer
- Rafael TejadaVice President of Investor Relations
- Thomas Bailey Shropshire Jr.Senior VP and General Counsel
- Sandy B. PoundVP & Chief Communications Officer
- Alan J. MalusSenior Vice President of Strategy & Corporate Development
Latest news about Thermo Fisher Scientific
Thermo Fisher sales increase 9% to $12.14 billion in Q3
United StatesQuantum BioPharma signs Phase 2 MS trial agreement
United StatesThermo Fisher posts 10% revenue growth to $11.99B
United StatesArcturus teams up with Thermo Fisher on mRNA therapy
United StatesThermo Fisher to divest microbiology business to Astorg for $1.075B
United StatesThermo Fisher revenue reaches $11.01B amid global life sciences demand
United States
Dividend history
Dividends per share paid by Thermo Fisher Scientific, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $1.4100 |
| FY2025 | — | — | — | $1.7200 |
| FY2024 | — | — | — | $1.5600 |
| FY2023 | — | — | — | $1.4000 |
| FY2022 | — | — | — | $1.2000 |
Key financials
Reported results for Thermo Fisher Scientific, in USD.
- Market cap
- 260.4B
- Revenue (TTM)
- 47.4B
- P/E ratio
- 37.1
- EPS (diluted, TTM)
- 19.0
- Dividend yield
- 0.1%
- Profit margin
- 14.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 44.6B | 8.1B | 6.7B | |
| 42.9B | 7.7B | 6.3B | |
| 42.9B | 6.9B | 6B | |
| 44.9B | 8.5B | 7B |